BioRestorative completes Phase 2 dosing of BRTX-100 in chronic lumbar disc disease trial, targets Q2 2027 data

Biorestorative

Biorestorative

BRTX

0.00
  • BioRestorative completed Phase 2 dosing in its BRTX-100 study for chronic lumbar disc disease, moving the program into blinded follow-up.
  • Topline safety and efficacy results are expected in Q2 2027; favorable blinded safety and preliminary efficacy findings have been presented previously.
  • The trial enrolled 99 patients in a randomized, double-blind, sham-controlled design, positioning the program for potential late-stage development planning.
  • Management pointed to lower spending following dosing completion, shifting resources toward Phase 3 readiness work and its BioCosmeceutical commercialization effort.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BioRestorative Therapies Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605261100PRIMZONEFULLFEED9725076) on May 26, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.